www.genomicexpression.com Open in urlscan Pro
35.156.117.131  Public Scan

Form analysis
0 forms found in the DOM

Text Content

 * About us and RNA
 * OneRNA in Cancer
 * OneRNA for Drug Development
 * Blog
 * …  
   * About us and RNA
   * OneRNA in Cancer
   * OneRNA for Drug Development
   * Blog


INVEST
 * About us and RNA
 * OneRNA in Cancer
 * OneRNA for Drug Development
 * Blog
 * …  
   * About us and RNA
   * OneRNA in Cancer
   * OneRNA for Drug Development
   * Blog


INVEST


 * SAVING LIVES NOW
   
   ONE CANCER PATIENT 
   
   AT THE TIME
   
    
   
   OUR ONERNA® PLATFORM ENABLES REPURPOSING OF APPROVED DRUGS ON AN INDIVIDUAL
   PATIENT BASIS AND RAPID DEVELOPMENT OF NOVEL RNA THERAPEUTICS
   
   Lean More
   
   ARE YOU A DOCTOR OR A PATIENT ?
   
   LOOKING FOR BETTER TREATMENT OPTIONS FOR YOUR PATIENTS? OUR ONERNA® PLATFORM
   ENABLES REPURPOSING APPROVED DRUGS ON AN INDIVIDUAL PATIENT BASIS
   
   Learn More
   
   ARE YOU DEVELOPING CURES?
   
   USING JUST ONE BIOMARKER CAN SAVE $1B DURING CLINICAL DEVELOPMENT.
   
   THE ONERNA PLATFORM MAKES THE COMPANION DIAGNOSTIC INTO AN ALGORITHM AND
   RAPIDLY TRANSLATES RNA CODE TO NOVEL RNA THERAPUTICS
   
   Learn More
   
   INVEST IN US
   
   HELP US LAUNCH ONERNA® IN WOMENS CANCERS
   
   WE ARE RAISING $1M+ IN PARALLEL WITH A SERIES A TO
   
   LAUNCH ONERNA® IN BREAST AND OVARIAN CANCER.
   
   AFTER OUR SERIES A WE CAN EXPAND INTO OTHER CANCERS.
   
   Learn More
   
   
   


 * THE ONERNA® PLATFORM
   
   BY ANALYZING RNA WE CAN MONITOR HEALTH, DETECT DISEASE, AND DESIGN
   NEXT-GENERATION CURES
    
   
   WHAT IS THE DIFFERENCE BETWEEN RNA AND DNA?
   
   RNA IS THE SOFTWARE OF THE CELL AND CAN INFORM US OF THE ACTUAL PRESENCE OF
   DISEASE, WHEREAS DNA IS THE HARDWARE AND MAINLY INFORMS US OF THE RISK OF
   DISEASE. DNA PANELS USED IN CANCER TISSUE ANALYSES UP TO 500 GENES TYPICALLY
   ONLY IDENTIFY ONE DRUG IN UP TO 40% OF THE CASES.
   
    
   
   WE DON'T LIKE GUESSING, AND THEREFORE WE ANALYZE ALL THE +20,000 MRNA’S IN
   THE SAMPLE. THIS MAKES OUR ONERNA® PLATFORM THE MOST POWERFUL PLATFORM IN THE
   INDUSTRY AND IT ENABLES THE IMPLEMENTATION OF AI INTO STANDARD OF CARE. THEY
   WAS Y WE BUILT IT IS TISSUE AND DISEASE AGNOSTIC AND EXPONENTIALLY SCALABLE.
   
    
   
   RNA IS CODING FOR PROTEINS AND PROTEINS ARE TARGETS FOR DRUGS. TODAY RNA IS
   DIRECTLY A TARGET FOR DRUGS AND A DRUG ITSELF.
   
    
   
   WE ARE PIONEERS IN ANALYZING RNA USING SEQUENCING AND OUR ONERNA® TEST HAS
   BEEN VALIDATED IN BREAST AND OVARIAN CANCER AND IDENTIFIES MULTIPLE TREATMENT
   OPTIONS AND/OR CLINICAL STUDIES FOR PRACTICALLY ALL PATIENTS.
   
    
   
   WE ARE NOW DEVELOPING METHODS TO RAPIDLY TRANSLATE RNA CODE TO RNA
   THERAPEUTICS TO FURTHER INDIVIDUALIZE TREATMENT.
   
    
   
   
    WHEN MAKING TREATMENT DECISIONS, KNOWLEDGE IS POWER.
   
   A CANCER DIAGNOSIS IS LIFE-CHANGING. ASK YOUR DOCTOR ABOUT THE TESTING
   OPTIONS, INCLUDING OUR ONERNA® TEST IN BREAST AND OVARIAN CANCER. ONERNA®
   ANALYSES ALL MRNA IN YOUR TUMOR’S TISSUE, WHICH MAY HELP INDIVIDUALIZE A
   TREATMENT PLAN. BECAUSE NO DRUGS ARE EFFECTIVE IN ALL PATIENTS, IT'S
   ESSENTIAL TO HAVE A PLAN FOR THE NEXT STEPS.
   
   
   Learn More


 * WHO WE ARE
   
   EXPERIENCED MANAGEMENT TEAM WITH STARTUP RNA
   
   GITTE PEDERSEN
   
   CEO AND CO-FOUNDER
   
   Gitte Pedersen, CEO is a former executive at Novo Nordisk. She has advised
   the Danish Government and early-stage biotech companies regarding their
   corporate development in the US
   
    
   
   Follow at Linkedin
   
   MORTEN PEDERSEN
   
   CSO AND COFOUNDER
   
   Morten Pedersen, CTO and co-founder holds a Ph.D in genomics. He has a very
   strong innovation track record with multiple key patents in genomics. Morten
   is the inventor of Genomic Expression’s sample prep technologies
    
   
   JESPER ZEUTHEN
   
   VP ONCOLOGY RESEARCH
   
   Jesper Zeuthen, CMO, is the co-founder of GeneMap and Topotarget (both had
   IPOs), and prior to that he established one of the laboratories that became
   the Danish Cancer Society.


 * WHO'S TALKING ABOUT US
   
   WE HAVE BEEN FEATURED IN FORBES TWICE, GEN, GENOMEWEB AND MEDWATCH. OUR
   INVESTORS INCLUDE BIOGEN FOUNDERS, HARVARD BUSINESS ANGELS, INVESTOR CIRCLE,
   PIPELINE ANGELS, AND A FAMILY OFFICE; CENTURION HOLDING IN NEW YORK.
   
    
   
   WE ARE A SPRINGBOARD ALUM COMPANY AND AMONG THE 500 WOMEN-OWNED TECHNOLOGY
   COMPANIES THEY HAVE SUPPORTED. GENOMIC EXPRESSION CAME IN #2 IN THE WOMEN’S
   FOUNDERS PITCH EVENT IN LA, WAS IN THE TOP 10 COMPANIES TO PITCH FOR SIR
   RICHARD BRANSON (VIRGIN AIRLINES) EXTREME TECHNOLOGY CHALLENGE, AND WAS
   INVITED TO DINNER WITH BRANSON ON NECKER’S ISLAND.
   
    
   
   WE HAVE BROUGHT THE COMPANY FROM IDEA TO COMMERCIALIZATION FOR GRANTS,
   REVENUE, AND ANGEL FUNDING, AND ARE NOW IMPLEMENTING CAPABILITIES TO RAPIDLY
   TRANSLATE RNA CODE TO NOVEL RNA THERAPUTICS IN COLLABORATIONS WITH BIOTECH
   AND PHARMA
   
    
   
   THIS IS OUR FOUNDER STORY:
   
   


 * ARTICLES, GRANTS, INVESTORS AND CUSTOMERS
   
   THESE ARE OUR SUPPORTERS, FUNDERS AND CUSTOMERS
   
   Grant 
   
   Genome Danmark
   
   Accelerator
   
   Impact Investor
   
   Investor
   
   Impact Investor
   
   #2 at WFN
   
   Top 10 XTC
   
   Horizon2020 grant
   
   Eurostars Grant
   
   MedTech Innovator Top 50
   
   Winner of the Lyfebulb-Helsinn Award
   
   Winner of the EIC Lifescience Award
   
   Featured in Forbes
   
   Won EUTop50 and invited to present at the European Parliament
   
   Presented at GSTIC addressing the UN sustainability goals in health
   
   Finals of the Blue Cross Blue Shields GuideWell competition for novel COVID19
   solutions
   
   In the semi-finals of the XPRIZE for Rapid Covid Testing - $6 million dollar,
   6-month competition to develop faster, cheaper, and easier to COVID-19
   testing methods at scale.
   
   XPrize Semifinalist Targets 300 Million Tests Per Day With Scalable COVID
   Self-Test


 * WANT TO LEARN MORE ?
   
   
   
   DISCLAIMER The information contained in our website is for general reference
   only, and should not be relied upon for any medical decision, or as a
   recommendation for any course of medical treatment. By 'opting-in' to our
   website, you understand we are not undertaking any responsibility to provide
   you with medical advice of any kind or character. There is no representation
   as to the accuracy or completeness of the information on our website, and we
   have no obligation to update or correct any posted information.


 * ITS BREAST CANCER AWARENESS MONTH
   
   BREAST CANCER DEATHS ARE DOWN, BUT OCCURRENCES ARE UP, PARTICULARLY AMONG
   YOUNGER WOMEN. THERE ARE MANY REASONS FOR THAT. ONE IS THE HORMONE DISRUPTORS
   LEAKING INTO OUR FOOD FROM PLASTIC CONTAINERS AND MICROPLASTIC, NOW
   EVERYWHERE. ANOTHER ONE IS HORMONE DISRUPTORS IN HAIR PRODUCTS AND OTHER
   TOXIC CHEMICALS IN HAIR, SKIN PRODUCTS, AND PERSONAL HYGIENE PRODUCTS SUCH AS
   TAMPONS THAT WOMEN USE REGULARLY. THE SKIN ABSORBS EVERYTHING YOU PUT ON
   IT.NO EFFECTIVE REGULATION IS IN PLACE, AND CHEMICALS BANNED IN EUROPE FOR
   DECADES ARE STILL USED IN THE USA.
   
   


 * YOU + SOCIAL MEDIA
   
   
   = SOCIAL IMPACT
   
   YOU'RE AWESOME. LET'S TALK.
   
   
   





@2024

Terms & Conditions
Privacy Policy





Call Us
Contact
Home
Store




Cookie Use
We use cookies to ensure a smooth browsing experience. By continuing we assume
you accept the use of cookies.
Accept
Learn More